The Efficiency for Stage II-III HR+/HER2+ Early Breast Cancer Patient With Standard Neoadjuvant Therapy in Real World.
Recruiting · NCT05263570 · Observational (researchers observe without assigning treatment) · Lead sponsor: Shengjing Hospital
View the official record on ClinicalTrials.gov →Interventions studied
Standard Therapy
What this trial is about
To observe the efficiency for patient with stage II-III HR+/HER2+ early breast cancer with standard neoadjuvant therapy, a retrospective, multicenter study in real world settings.
Who can take part
Age range
18 Years and older
Sex
Female
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- Age ≥18 years or older
- HR+/HER2- breast cancer diagnosis based on local standards
- Women having stage II-III breast cancer diagnosed based on AJCC cancer staging system (8th edition) who will be admitted because of breast cancer for the first time
- Standard Therapy, determined at the discretion of the investigator, including （TCbHP/THP/EC-THP/AC-THP）
- Complete medical history was available
- Karnofsky Performance Status (KPS) Scale score ≥ 70
Exclusion criteria
- Women who have received any form of anti-tumor treatment - (chemotherapy, radiotherapy, molecular targeted therapy, or endocrine therapy)
- Pregnant or breast-feeding women
- Those who have bilateral breast cancer, inflammatory breast cancer or occult breast cancer
- Those who have stage IV breast cancer
Where it is running
1 location listed.
- Shengjing Hospital of China Medical University - Shenyang, Liaoning, China